Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | Filip Janku, Gopa Iyer, Anna Spreafico, Noboru Yamamoto, Yung-Jue Bang, Elena Elez, Maja J. De Jonge, Harry J.M. Groen, Frederik Marmé, Kathrin Gollmer, Annie St-Pierre, Maritza Melendez, Anna Mais, Heidi Nauwelaerts, Uz M. Stammberger, Reinhard Dummer |
Title | A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations. |
Journal | J Clin Oncol |
Vol | |
Issue | |
Date | |
URL | https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2586 |
Abstract Text | J Clin Oncol 36, no. 15_suppl (May 20 2018) 2586-2586 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF mutant | Advanced Solid Tumor | predicted - sensitive | LXH 254 | Case Reports/Case Series | Actionable | In a Phase I trial, LXH 254 treatment resulted in partial response in 2.6% (2/75) and stable disease in 33% (25/75) of patients with advanced solid tumors harboring MAPK pathway alterations, one of the patient achieved partial response harbored a BRAF mutation (J Clin Oncol 36, no. 15_suppl (May 20 2018) 2586-2586; NCT02607813). | detail... |